Approval based on INAVO120 data showing the Itovebi™ (inavolisib)-based regimen more than doubled progression-free survival ...

Roche ( OTCQX:RHHBY) ( OTCQX:RHHBF) ( OTCPK:RHHVF) said that the European Commission has approved its oral cancer drug, ...

Basel: Roche has received approval from the European Commission for Itovebi (inavolisib), in combination with palbociclib ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved Itovebi ...

Itovebi-based regimen significantly improved OS and PFS in PIK3CA-mutated, HR-positive, HER2-negative breast cancer patients. The FDA approved the Itovebi-based combination in October 2024 for ...

New Data Show Genentech’s Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer – The Itovebi (inavolisib)-based regimen reduced the risk of death by ...

The U.S. Food and Drug Administration (FDA) approved the Itovebi-based regimen in October 2024 for the treatment of adults with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative ...

Itovebi, Ibrance, and Faslodex significantly improved OS in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer compared to placebo. The INAVO120 trial showed a median OS of 34.0 months ...

FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation. Oct. 10, 2024 4:10 PM ET Roche Holding AG (RHHBY) ...

Roche’s Itovebi gets European approval to treat people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation: Basel Thursday, July 24, 2025, 09:00 Hrs [ ...

Genentech, a member of the Roche Group, announced today positive topline results from the overall survival analysis of the Phase III INAVO120 study investigating Itovebi TM in combination with ...